You are here
Adderall Sales in Canada Suspended, FDA Responds
FDA is issuing a Public Health Advisory and information sheets on its website at www.fda.gov in order to address questions that may arise from the Canadian announcement and to provide up-to-date information about Adderall’s safety profile.
Patients using Adderall (or parents of children on the drug) who have questions about this medication should consult their physicians before making any alterations to their therapy.
As with any drug, FDA will continue to carefully assess any new data that emerges which significantly affects the safety profile of this drug and will take immediate, appropriate action to promote the public health and make the public aware of its findings.
To view the Canadian advisory, click here: http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_01.html.
Source: The Food and Drug Administration